Karyopharm Therapeutics (KPTI) Aktienübersicht
Karyopharm Therapeutics Inc. ist ein pharmazeutisches Unternehmen im kommerziellen Stadium, das Medikamente zur Behandlung von Krebs und anderen Krankheiten in den Vereinigten Staaten entdeckt, entwickelt und vermarktet, die sich gegen den Kernexport richten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 2/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
+ 1 mehr Risiko
KPTI Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Karyopharm Therapeutics Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$1.95 |
| 52-Wochen-Hoch | US$10.99 |
| 52-Wochen-Tief | US$1.80 |
| Beta | 0.95 |
| 1 Monat Veränderung | -80.60% |
| 3 Monate Veränderung | -77.43% |
| 1 Jahr Veränderung | -50.88% |
| 3 Jahre Veränderung | -92.22% |
| 5 Jahre Veränderung | -97.30% |
| Veränderung seit IPO | -99.19% |
Aktuelle Nachrichten und Updates
Narrative-Update • Aug 05
KPTI: FDA Feedback On Myelofibrosis Will Support Bullish Repricing
Analysts have lowered the fair value estimate for Karyopharm Therapeutics from $16.00 to $11.00, reflecting reduced price targets after mixed trial updates. Myelofibrosis prospects are supported by FDA feedback, while endometrial cancer data and a recent downgrade temper overall expectations.Narrative-Update • Jul 22
KPTI: Reset Expectations And Misunderstood Compensation Plan Will Support Bullish Repricing
Karyopharm Therapeutics' updated analyst price target of $16, reduced from $23, reflects a reset in fair value assumptions along with revised expectations for revenue growth, profit margins, and future P/E. Analysts point to recent stock weakness around the compensation plan as a potential misread rather than a change in the underlying story.Seeking Alpha • Jul 21
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead
Summary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking AlphaRecent updates
Narrative-Update • Aug 05
KPTI: FDA Feedback On Myelofibrosis Will Support Bullish Repricing
Analysts have lowered the fair value estimate for Karyopharm Therapeutics from $16.00 to $11.00, reflecting reduced price targets after mixed trial updates. Myelofibrosis prospects are supported by FDA feedback, while endometrial cancer data and a recent downgrade temper overall expectations.Narrative-Update • Jul 22
KPTI: Reset Expectations And Misunderstood Compensation Plan Will Support Bullish Repricing
Karyopharm Therapeutics' updated analyst price target of $16, reduced from $23, reflects a reset in fair value assumptions along with revised expectations for revenue growth, profit margins, and future P/E. Analysts point to recent stock weakness around the compensation plan as a potential misread rather than a change in the underlying story.Seeking Alpha • Jul 21
Karyopharm Therapeutics: Balance Sheet Poor But Catalysts Ahead
Summary Karyopharm Therapeutics markets Xpovio (selinexor) in multiple myeloma and is running trials in multiple myeloma, myelofibrosis, and endometrial cancer, with key clinical catalysts ahead. The SENTRY trial in myelofibrosis patients showed mixed results on the co-primary endpoints, but a preliminary survival benefit may strengthen with mature data. Prior SIENDO trial data in endometrial cancer revealed a potential benefit for selinexor in certain subgroups, supporting the upcoming XPORT-EC-042 readout. KPTI faces cash burn and debt concerns, but positive trial results and potential treatment guideline inclusion for selinexor in myelofibrosis could provide it with strategic options. Read the full article on Seeking Alpha
Narrative-Update • Jul 08
KPTI: Elevated Expectations For 2026 Revenue Will Likely Constrain Future Upside
Analysts have raised their fair value estimate for Karyopharm Therapeutics from $5.00 to $7.31, citing updated assumptions about discount rates, revenue growth, profit margins, and future P/E, which are reflected in recent price target increases from the Street. Analyst Commentary Recent Street research on Karyopharm Therapeutics highlights a mix of optimism around the company’s potential and caution around how that potential is reflected in the stock price.
Narrative-Update • Jun 24
KPTI: Phase 3 Myelofibrosis Data Will Shape 2026 Risk Reward Profile
Analysts have adjusted their outlook on Karyopharm Therapeutics with a revised consensus price target, reflecting shifts in recent $5 and $8 upward revisions and $7 and $4 downward revisions as they reassess the company's risk profile and long term earnings potential. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a split view, with some firms revising price targets upward and others marking them down.Narrative-Update • Jun 07
KPTI: Phase 3 Myelofibrosis Data Will Drive 2026 Frontline Opportunity
Analysts have revised their price target on Karyopharm Therapeutics, citing updated views on fair value, growth, and profitability assumptions. The new target is $13.50, compared with the prior $15.33.Narrative-Update • May 03
KPTI: Selinexor Commercialization And Funding Pressures Will Likely Constrain Future Upside
Analyst price targets for Karyopharm Therapeutics have shifted, with recent cuts and a subsequent $8 increase tied to reassessments of revenue potential, profit margins and future P/E assumptions around selinexor and the broader pipeline. Analyst Commentary Recent Street research on Karyopharm Therapeutics shows a mixed picture, with one price target increase following several cuts over a relatively short window.Narrative-Update • Apr 19
KPTI: Funding Uncertainty And Execution Risks Will Likely Cap Future Returns
Analysts have trimmed their average price target on Karyopharm Therapeutics by several dollars, citing updated views on discount rates, revenue assumptions and long term profit margins following recent Street research. Analyst Commentary Recent Street research shows several bearish analysts cutting their Karyopharm price targets by mid single digit to high single digit dollar amounts, pointing to revised assumptions on discount rates, revenue potential and long term margins.Narrative-Update • Apr 04
KPTI: Funding Strains And Execution Risks Will Likely Restrain Future Upside
The Street’s blended fair value estimate for Karyopharm has been trimmed by $1.00 to $5.00, as analysts fold in lower projected revenue growth, a slightly softer profit margin outlook, a higher discount rate, and updated P/E assumptions following recent target cuts from multiple firms. Analyst Commentary Recent Street research has tilted more cautious on Karyopharm, with multiple bearish analysts cutting price targets and reassessing the risk profile around execution, profitability, and the timing and scale of future revenue contributions.Narrative-Update • Mar 21
KPTI: Phase 1 Myelofibrosis Data Will Support 2026 Frontline Opportunity
Analysts have adjusted their price target for Karyopharm Therapeutics to $28, citing confidence in selinexor's differentiated mechanism of action, compelling Phase 1 data in myelofibrosis, and a projected peak revenue opportunity of $800m to $850m in frontline myelofibrosis, with further potential from multiple myeloma programs. Analyst Commentary Bullish Takeaways Bullish analysts see selinexor's differentiated mechanism of action as a key driver for long term value, supporting the $28 price target as they factor in a distinct clinical profile within myelofibrosis.Narrative-Update • Mar 07
KPTI: Refreshed Revenue And Margin Outlook Will Support Bullish Repricing
Analysts have updated their price target on Karyopharm Therapeutics from $66.25 to $23.00, citing refreshed assumptions around revenue growth, profit margins, discount rate, and future P/E following recent bullish Street research. Analyst Commentary Bullish analysts are framing the reset in price target to $23.00 as part of a broader constructive view on Karyopharm Therapeutics, where refreshed modeling assumptions are more closely aligned with recent positive Street research.Narrative-Update • Feb 20
KPTI: Execution And Funding Risks Will Likely Cap Bullish Repricing
Analysts have raised their $6.00 price target for Karyopharm Therapeutics, citing slightly lower perceived risk, a modestly stronger revenue outlook, and a small increase in the expected future P/E as the key factors behind the update. Analyst Commentary Recent research commentary around Karyopharm Therapeutics has centered on how much risk investors should assign to the story, how sustainable the current revenue trajectory may be, and what a reasonable P/E might look like given execution needs ahead.Narrative-Update • Feb 06
KPTI: Lower Risk View Will Support 2026 Myelofibrosis Phase III Milestone
Analysts have modestly raised their price target on Karyopharm Therapeutics to US$15.33, citing a slightly lower required return and similar long term growth and margin assumptions that keep the fair value estimate steady. Analyst Commentary Recent Street research has focused on how the updated price target for Karyopharm Therapeutics lines up with its risk profile and execution needs, rather than materially changing long term growth or margin assumptions.Narrative-Update • Jan 23
KPTI: Extended Cash Runway Will Support 2026 Myelofibrosis Phase III Milestone
Narrative update on Karyopharm Therapeutics Analysts have nudged their fair value estimate for Karyopharm Therapeutics higher from US$14.67 to US$15.33, citing recent Street research that points to steady Xpovio sales, reduced financing overhangs, maintained MF timelines into March 2026, and updated price targets that reflect the latest financing transactions. Analyst Commentary Recent Street research highlights a mix of optimism around execution and caution around financing and valuation as analysts update their views on Karyopharm Therapeutics.Analyseartikel • Jan 11
Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Prospects Need A Boost To Lift Shares
You may think that with a price-to-sales (or "P/S") ratio of 1.1x Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) is...Narrative-Update • Jan 09
KPTI: Financing Overhangs Will Likely Outweigh MF Timeline Support
Analysts have trimmed their 12 month price target on Karyopharm Therapeutics to US$19 from US$30, citing recent financing transactions. They also point to solid Xpovio sales and maintained MF timelines into March 2026 as support for the stock’s overall risk and reward profile.Narrative-Update • Dec 25
KPTI Extended Cash Runway Will Likely Be Outweighed By Dilution Risk
Analysts have cut their price target on Karyopharm Therapeutics to about $6 from roughly $8 per share, citing the impact of recent financing transactions on valuation. At the same time, extended cash runway, solid Xpovio sales and visibility into key 2026 myelofibrosis data support a still constructive risk and reward profile.Narrative-Update • Dec 11
KPTI: Extended Cash Runway Will Support Pivotal 2026 Myelofibrosis Phase III Readout
Analysts have modestly reduced their price targets on Karyopharm Therapeutics, trimming expectations from a prior average in the low $20s to the high teens. Recent financing transactions extend the cash runway into 2026 and also dilute near term upside, despite a solid outlook for Xpovio sales and key myelofibrosis data in 2026.Narrative-Update • Nov 27
KPTI: Extended Cash Runway Will Support Key Myelofibrosis Phase III Data
Analysts have lowered their price targets on Karyopharm Therapeutics, with reductions such as $19 from $30 and $6 from $8. They cite the impact of recent financing transactions while maintaining positive views on the company's risk profile and its cash runway extension, which is expected to support upcoming trial milestones.Narrative-Update • Nov 11
KPTI: Upcoming Myelofibrosis Phase III Readout Will Drive Future Opportunity
Karyopharm Therapeutics’ analyst fair value price target has decreased by $1.00 to $14.67. Analysts cite recent financing transactions and updated growth forecasts as key factors behind the revision.Narrative-Update • Oct 28
Extended Cash Runway Will Support Pivotal Phase III Clinical Milestones
Karyopharm Therapeutics' analyst price target has been reduced sharply from approximately $23.07 to $15.67 per share. Analysts cite the company’s recent strategic financing measures and updated projections following extended cash runway and upcoming clinical milestones.Narrative-Update • Oct 13
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics' analyst price target has been reduced from $8 to $6. This reflects analysts' views that, while strategic financing has extended the company's cash runway into Q2 2026, financial constraints and the timeline to key clinical trial readouts warrant a tempered outlook.Analyseartikel • Sep 11
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Held Back By Insufficient Growth Even After Shares Climb 65%
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shares have had a really impressive month, gaining 65% after a shaky...Narrative-Update • Aug 15
Phase III Trials And Global Partnerships Will Advance Personalized Medicine
Karyopharm Therapeutics’ net profit margin has improved and its future P/E has declined—indicating stronger profitability and a more attractive valuation—while the consensus analyst price target remains unchanged at $25.92. What's in the News Provided 2025 earnings guidance, expecting total revenue between $140 million and $155 million, including U.S. XPOVIO net product and partner-derived revenue.Analyseartikel • Aug 14
US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results
NasdaqGS:KPTI 1 Year Share Price vs Fair Value Explore Karyopharm Therapeutics's Fair Values from the Community and...Analyseartikel • May 24
Investors Don't See Light At End Of Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) Tunnel And Push Stock Down 27%
Unfortunately for some shareholders, the Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) share price has dived 27% in the...Analyseartikel • May 22
Here's Why Shareholders May Want To Be Cautious With Increasing Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Pay Packet
Key Insights Karyopharm Therapeutics' Annual General Meeting to take place on 28th of May CEO Richard Paulson's total...
Neues Narrative • Apr 08
Phase III SENTRY And XPOVIO Approvals Will Secure Future Success
Positive trial outcomes in myelofibrosis and endometrial cancer could significantly boost revenue and redefine care standards.Analyseartikel • Dec 24
Lacklustre Performance Is Driving Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) 27% Price Drop
Karyopharm Therapeutics Inc. ( NASDAQ:KPTI ) shareholders won't be pleased to see that the share price has had a very...Aktionärsrenditen
| KPTI | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -72.2% | 1.9% | 3.5% |
| 1Y | -50.9% | 39.1% | 20.5% |
Rendite im Vergleich zur Industrie: KPTI unter dem Niveau der Branche US Biotechs , die im vergangenen Jahr eine Rendite von 39.1% erzielte.
Rendite vs. Markt: KPTI hinter dem Markt US zurück, der im vergangenen Jahr eine Rendite von 20.5 erzielte.
Preisvolatilität
| KPTI volatility | |
|---|---|
| KPTI Average Weekly Movement | 23.4% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: Der Aktienkurs von KPTI war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: KPTIDie wöchentliche Volatilität der Aktie ist im vergangenen Jahr von 17% auf 23% gestiegen.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2008 | 228 | Richard Paulson | www.karyopharm.com |
Karyopharm Therapeutics Inc. ist ein pharmazeutisches Unternehmen im Entwicklungsstadium, das Medikamente gegen den Kernexport zur Behandlung von Krebs und anderen Krankheiten in den Vereinigten Staaten entdeckt, entwickelt und vermarktet. Das Unternehmen erforscht, entwickelt und vermarktet neuartige und niedermolekulare selektive Inhibitoren des Kernexports (SINE), die das Kernexportprotein Exportin 1 (XPO1) hemmen. Zu den führenden Wirkstoffen gehören XPOVIO in Kombination mit Bortezomib und Dexamethason für die Behandlung erwachsener Patienten mit multiplem Myelom, in Kombination mit Dexamethason für die Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem multiplem Myelom und für die Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom (DLBCL).
Karyopharm Therapeutics Inc.'s Grundlagenzusammenfassung
| KPTI grundlegende Statistiken | |
|---|---|
| Marktanteil | US$43.29m |
| Gewinn(TTM) | -US$194.97m |
| Umsatz(TTM) | US$151.12m |
0.3x
Kurs-Umsatz-Verhältnis-0.2x
Kurs-Gewinn-Verhältnis Ist KPTI zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| KPTI Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$151.12m |
| Kosten der Einnahmen | US$130.79m |
| Bruttogewinn | US$20.33m |
| Sonstige Ausgaben | US$215.30m |
| Gewinn | -US$194.97m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -8.60 |
| Bruttomarge | 13.45% |
| Nettogewinnspanne | -129.02% |
| Schulden/Eigenkapital-Verhältnis | -111.7% |
Wie hat sich KPTI auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/06 20:27 |
| Aktienkurs zum Tagesende | 2026/08/06 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Karyopharm Therapeutics Inc. wird von 20 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Colleen Kusy | Baird |
| Ying Huang | BofA Global Research |
| Harshita Polishetty | B. Riley Securities, Inc. |